K-Ras(G12C) inhibitor 6 is primarily used in cancer research and treatment, specifically targeting cancers driven by the K-Ras(G12C) mutation. This mutation is commonly found in various cancers, including non-small cell lung cancer (NSCLC), colorectal cancer, and pancreatic cancer. The inhibitor works by selectively binding to the mutated K-Ras protein, blocking its activity and preventing the uncontrolled cell growth and division characteristic of cancer. Its application in preclinical and clinical studies has shown promise in reducing tumor growth and improving patient outcomes. Additionally, it serves as a valuable tool in understanding the molecular mechanisms of K-Ras-driven cancers and in developing more effective targeted therapies.